Celcuity IncNASDAQ:CELC
- LAST PRICE12.8600
- TODAY'S CHANGE (%)0.0100 (0.0778%)
- Bid / Lots12.8400/ 3
- Ask / Lots12.8800/ 2
- Open / Previous Close12.8800 / 12.8500
- Day Range
- 52 Week Range
- Volume65,658
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CELC |
|---|---|---|
| 09:32 ET | 1659 | 12.975 |
| 09:33 ET | 400 | 12.955 |
| 09:35 ET | 279 | 12.955 |
| 09:37 ET | 800 | 12.923 |
| 09:39 ET | 513 | 12.88 |
| 09:42 ET | 600 | 12.8 |
| 09:44 ET | 200 | 12.76 |
| 09:48 ET | 401 | 12.76 |
| 09:55 ET | 891 | 12.715 |
| 10:00 ET | 100 | 12.69 |
| 10:02 ET | 300 | 12.76 |
| 10:04 ET | 100 | 12.795 |
| 10:13 ET | 873 | 12.805 |
| 10:15 ET | 1275 | 12.87 |
| 10:18 ET | 535 | 12.86 |
| 10:20 ET | 230 | 12.865 |
| 10:27 ET | 712 | 12.84 |
| 10:29 ET | 829 | 12.84 |
| 10:38 ET | 568 | 12.87 |
| 10:40 ET | 205 | 12.835 |
| 10:44 ET | 649 | 12.835 |
| 10:51 ET | 1512 | 12.915 |
| 10:54 ET | 135 | 12.915 |
| 10:56 ET | 107 | 12.915 |
| 10:58 ET | 100 | 12.89 |
| 11:00 ET | 100 | 12.88 |
| 11:03 ET | 200 | 12.87 |
| 11:05 ET | 475 | 12.85 |
| 11:07 ET | 100 | 12.825 |
| 11:12 ET | 2467 | 12.835 |
| 11:18 ET | 1010 | 12.86 |
| 11:20 ET | 100 | 12.84 |
| 11:25 ET | 500 | 12.93 |
| 11:27 ET | 403 | 12.84 |
| 11:30 ET | 200 | 12.85 |
| 11:32 ET | 100 | 12.855 |
| 11:34 ET | 300 | 12.81 |
| 11:36 ET | 104 | 12.78 |
| 11:38 ET | 112 | 12.78 |
| 11:41 ET | 300 | 12.82 |
| 11:43 ET | 100 | 12.82 |
| 11:45 ET | 400 | 12.82 |
| 11:48 ET | 800 | 12.8 |
| 11:50 ET | 357 | 12.815 |
| 11:52 ET | 100 | 12.83 |
| 11:54 ET | 301 | 12.83 |
| 11:56 ET | 200 | 12.81 |
| 11:57 ET | 439 | 12.76 |
| 11:59 ET | 404 | 12.765 |
| 12:01 ET | 211 | 12.75 |
| 12:03 ET | 200 | 12.8 |
| 12:06 ET | 335 | 12.76 |
| 12:08 ET | 100 | 12.8 |
| 12:10 ET | 500 | 12.78 |
| 12:14 ET | 340 | 12.77 |
| 12:17 ET | 200 | 12.73 |
| 12:21 ET | 100 | 12.73 |
| 12:24 ET | 930 | 12.785 |
| 12:26 ET | 796 | 12.785 |
| 12:28 ET | 200 | 12.785 |
| 12:30 ET | 3704 | 12.83 |
| 12:32 ET | 1019 | 12.79 |
| 12:33 ET | 309 | 12.8 |
| 12:35 ET | 100 | 12.83 |
| 12:37 ET | 500 | 12.81 |
| 12:39 ET | 600 | 12.86 |
Nov 15, 2024
DJ Celcuity Price Target Maintained With a $27.00/Share by HC Wainwright & Co., from 2:38PM ET on Friday Nov 15, 2024 by Dow Jones
2:38PM ET on Friday Nov 15, 2024 by Dow JonesDJ Celcuity Down Over 12%, on Pace for Largest Percent Decrease Since October 2023 -- Data Talk, from 1:42PM ET on Friday Nov 15, 2024 by Dow Jones
1:42PM ET on Friday Nov 15, 2024 by Dow JonesDJ Celcuity Price Target Maintained With a $23.00/Share by Needham, from 5:16AM ET on Friday Nov 15, 2024 by Dow Jones
5:16AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 14, 2024
Press Release: Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update, from 4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
4:01PM ET on Thursday Nov 14, 2024 by Dow JonesCelcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update, from 4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Celcuity Inc | 477.1M | -4.9x | --- |
GH Research PLC | 482.8M | 0.0x | --- |
ACELYRIN Inc | 465.5M | -1.7x | --- |
Kalvista Pharmaceuticals Inc | 495.2M | -2.8x | --- |
Terns Pharmaceuticals Inc | 499.4M | -5.2x | --- |
Aura Biosciences Inc | 449.6M | -5.4x | --- |
Company Information
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Contact Information
- Headquarters
- 16305 36th Ave N Ste 100MINNEAPOLIS, MN, United States 55446-4285
- Phone
- 763-392-0767
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer, Co-Founder
- Brian Sullivan
- Co-Founder, Chief Science Officer, Vice President, Secretary, Director
- Lance Laing
- Chief Financial Officer
- Vicky Hahne
- Chief Commercial Officer
- Eldon Mayer
- Independent Director
- Richard Buller
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $477.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 37.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-2.61 |
Book Value | $5.48 |
P/E Ratio | -4.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
